Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Li...( 2 SVR the protocol specified primary ...),Health

2 SVR, the protocol specified primary efficacy endpoint, is defined as

achievement of undetectable HCV-RNA in plasma at 24 weeks after the end

of treatment. Per protocol, if a patient did not have a 24-week post-

treatment assessment, the patient's 12-week post-treatment assessment

was utilized.

3 Roche Cobas Taqman 1.0 assay; lower limit of quantitation (LLQ) is 27

IU/mL.

4 Intention-To-Treat (ITT) analysis includes any patient who has taken at

least one dose of any study drug.

5 Sensitivity Analysis: Patients with missing data at follow-up week 24

are included in the analysis if treatment week 4 and treatment week 24

undetectable (HCV-RNA): PPVs at treatment week 4 were 94 vs. 91 vs. 89

percent for the PEGINTRON 1.5 mcg arm, PEGINTRON 1.0 mcg arm and Pegasys

arm, respectively.